SOFIVA Genomics (6615) participated in the Healthcare+ Expo Taiwan 2021 (Booth: L218) on December 4th, and held a symposium on “Building Your Exclusive Health Care in the New Era of Precision Medicine” at the Expo, where Dr. Xiang-Hong Lin, attending physician of the Department of Gastroenterology and Hepatology of Mackay Memorial Hospital, Dr. Shun-Ren Que, attending physician of the Department of Urology of Dianthus Medical Group, and Dr. Chia-Cheng Hung, general manager of SOFIVA Genomics were invited to share with the public the coming era of precision medicine, using genetic testing for identifying cancer-causing cells and medical assistance in devising an individualized treatment plan. Chia-Cheng Hung, general manager of SOFIVA Genomics, pointed out "Precision medicine has become one of the global medical development trends. As the public is increasingly understanding the concept of precision medicine, SOFIVA Genomics has shown growth of its cancer detection business since its launch in 2017. Tthe average monthly income in the second half of 2021 is more than three times that of 2017. In the future, SOFIVA Genomics will actively develop more genetic testing products to satisfy the needs of clinical medicine applications and help to accelerate development of precision medicine in Taiwan."
Traditional cancer screenings such as imaging screenings must be exposed to the risks of radiation and contrast agents, and invasive tissue biopsy may cause great psychological pressure on patients. In the new era of precision medicine, genetic testing has the ability to detect 30 types of cancer through a single blood draw, including breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, gastric cancer, ovarian cancer, endometrial cancer and so forth. Dianthus Medical Group is about to set up a health checkup center, combined with SOFIVA Genomics' professional testing services to provide the most advanced inspection equipment and the most experienced and professional medical team in order to develope high quality medical care tailored to the individual’s health needs.
In recent years, National Health Insurance has accelerated the payment of multiple targeted cancer drugs and pre-medication accompanying tests. The public and physicians have a better understanding of the importance and application effects of genetic testing and targeted drugs. Chia-Cheng Hung, general manager of SOFIVA Genomics, expressed that cancer testing submissions this year has increased significantly. Compared with the time when it was launched in 2017, the average monthly revenue this year is more than three times that of 2017. The increasingly popular precision medicine not only allows more patients to receive related medication payments, but also provides doctors and patients with the most suitable treatment program or drug judgments through various types of testings, thereby improving the effect of disease treatment, and also giving doctors more options for cancer treatment. SOFIVA Genomics will continue to provide the most advanced and complete genetic testing Service, advocate the concept of preventive medicine, and protect everyone’s health."